US FDA Approves Amgen Drug for Small Cell Lung Cancer

Source: Reuters

The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen’s (AMGN.O), tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung cancer that has worsened despite chemotherapy.

The drug, marketed under the name Imdelltra, is part of Amgen’s pipeline of bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body’s immune system can kill the cancer.